An interventional study of Vitamin D2 and placebo in Healthy Volunteers, sponsored by Peking University Third Hospital. Status unknown at 1 site in China. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-01-06.
Sponsored by Peking University Third Hospital · Not applicable, Interventional, and Prevention
A total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin D2 and the group not taking vitamin D2. Participants in the group taking vitamin D2 orally will receive 200,000 IU of vitamin D2 on the first day of the trial, and again two weeks later (200,000 IU) . The group that will not receive vitamin D2 will not receive any intervention. The whole trial will laste four weeks.
This study is a randomized controlled multicenter clinical trial. Participants who meet the inclusion criteria can be included in this trial after signing informed consent. A total of 218 participants will be included in this study, and will be randomly assigned 1:1 to the group taking vitamin D2 and the group not taking vitamin D2. Participants in the group taking vitamin D2 orally will receive 200,000 IU of vitamin D2 on the first day of the trial, and again two weeks later (200,000 IU) . The group that will not receive vitamin D2 will not receive any intervention. The whole trial will laste four weeks. Throughout the trial, participants' nucleic acid or antigen results, 25(OH)D concentrations, etc., need to be tested.
Peking University Third Hospital is the lead sponsor of 735 studies on the registry; 262 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Oral dose of Vitamin D2 every two weeks
Drug: Vitamin D2
Without any intervention
Other: placebo
Participants in the vitamin D2 group received 200,000 IU of vitamin D2 orally on the first day of the trial and again two weeks later
Also known as: cholecalciferol
This group will not do any intervention
Change in incidence of laboratory-confirmed (or COVID-19 antibody test) COVID-19 infection
The test will be nucleic acid or antigen testing twice a week for four weeks
Time frame: 4 weeks
The duration of a positive to negative antigen test after infection with COVID-19
Antigen test results were recorded twice a week for four weeks
Time frame: up to 4 weeks
The duration of symptoms in COVID-19 positive participants
For COVID-19 positive participants, symptoms will be recorded on a questionnaire twice a week.
Time frame: up to 4 weeks
The proportion of participants whose symptoms of COVID-19 infection were confirmed by antigen testing for more than 7 days
For COVID-19 positive participants, symptoms will be recorded on a questionnaire twice a week.
Time frame: 4 weeks
The proportion of asymptomatic COVID-19 infected persons (those who test positive for the etiology of COVID-19 but have no related clinical manifestations)
For COVID-19 positive participants, symptoms will be recorded on a questionnaire twice a week.
Time frame: 4 weeks
This study is status unknown, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Peking University Third Hospital